Drug Profile
Research programme: PCSK9 protein inhibitors - Serometrix
Alternative Names: SX PCK9Latest Information Update: 14 Feb 2022
Price :
$50
*
At a glance
- Originator Serometrix
- Class Small molecules
- Mechanism of Action PCSK9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hypercholesterolaemia
Most Recent Events
- 28 Apr 2019 No recent reports of development identified for preclinical development in Hypercholesterolaemia in USA (PO)
- 16 Mar 2015 PCSK9 protein inhibitors are available for licensing as of 16 Mar 2015. http://www.serometrix.com/partnering.html
- 16 Mar 2015 Preclinical trials in Hypercholesterolaemia in USA before March 2015 (Parenteral)